Allurion Technologies Inc.

Equities

ALUR

US02008G1022

Software

Market Closed - Nyse 04:00:02 2024-05-01 pm EDT 5-day change 1st Jan Change
2.35 USD +16.92% Intraday chart for Allurion Technologies Inc. +30.56% -37.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the First Quarter 2024 CI
Allurion Technologies Inc. announced that it has received $48 million in funding from RTW Investments, LP CI
Allurion Technologies Inc. amended terms of the transaction CI
Allurion Technologies Inc. announced that it expects to receive funding from RTW Investments, LP CI
Sector Update: Health Care Stocks Slump Late Afternoon MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Sector Update: Health Care MT
Top Midday Gainers MT
Allurion Technologies' Shares, Trading Volume Jump After US Launch of Weight-Loss System MT
Chardan Initiates Allurion Technologies With Buy Rating, Price Target is $5 MT
Allurion Technologies, Inc. Expands Virtual Care Suite to the United States CI
Earnings Flash (ALUR) ALLURION TECHNOLOGIES Reports Q4 Revenue $8.2M MT
Allurion Technologies Inc. Reiterates Earnings Guidance for the Full Year 2024 CI
Allurion Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Allurion Technologies Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Allurion Technologies Inc. Appoints Milena Alberti-Perez as Board of Directors as Audit Committee Chair CI
Jefferies Starts Allurion Technologies With Buy Rating, $5 Price Target MT
Allurion Technologies Inc. Appoints Brendan Gibbons as Its New Chief Legal Officer and Corporate Secretary CI
Somerset NHS Foundation Trust Treats First Patients with Allurion Balloon for Pre-Surgical Weight Loss CI
Allurion Technologies, Inc.'s Virtual Care Suite Digital Platform Accelerates Commercial Expansion With New Strategic Partnerships CI
Allurion Technologies Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2023 and Full Year of 2024 CI
Allurion Technologies Inc. Announces New Research Highlights the Positive Impact of GLP-1s and Other Anti-Obesity Medications on the Allurion Program CI
Allurion Technologies, Inc. Announces an Expanded Commercial Agreement with Weight Doctors CI
Allurion Technologies Inc.(NYSE:ALUR) added to S&P Global BMI Index CI
Allurion Technologies Inc. Announces Resignation of Chief Commercial Officer, Benoit Chardon, Effective December 31, 2023 CI
Chart Allurion Technologies Inc.
More charts
Allurion Technologies, Inc. offers Allurion Program, which is a weight loss platform that combines the Allurion Gastric Balloon for weight loss. The Company offers Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Iris AI Platform and health tracker devices. Its health tracker devices include Allurion Connected Scale and Allurion Health Tracker. Allurion Connected Scale offers a complete weight tracking experience, allowing users to monitor their weight, body mass index (BMI) and body composition. Allurion Health Tracker tracks steps, exercise and sleep. Allurion Virtual Care Suite is available to providers separately from the Allurion Program to help customize, monitor and manage weight-loss therapy for patients regardless of their treatment plan, which includes gastric balloon, surgical and medical or nutritional. Its Allurion Programme is offered in six months, 12 months and 12-18 months program.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.35 USD
Average target price
5 USD
Spread / Average Target
+112.77%
Consensus

Quarterly revenue - Rate of surprise